Piritramide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Piritramide
Accession Number
DB12492
Description

Piritramide is under investigation for the treatment of Colon Cancer and Minimal Residual Disease. Piritramide has been investigated for the supportive care of Pain, Postoperative and Postoperative Nausea and Vomiting.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 430.5851
Monoisotopic: 430.27326173
Chemical Formula
C27H34N4O
Synonyms
  • Piritramida
  • Piritramide
  • Piritramidum
External IDs
  • IDS-NP-013
  • R 3365
  • R-3365

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Piritramide.
AcetophenazineThe risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Piritramide.
AclidiniumThe risk or severity of adverse effects can be increased when Piritramide is combined with Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Piritramide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Piritramide.
AlimemazineThe risk or severity of hypotension and CNS depression can be increased when Alimemazine is combined with Piritramide.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Piritramide.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Piritramide.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Piritramide.
AlprazolamThe risk or severity of adverse effects can be increased when Piritramide is combined with Alprazolam.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

International/Other Brands
Dipidolor / Piridolan

Categories

ATC Codes
N02AC03 — Piritramide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylacetonitriles. These are cyclic aromatic compounds containing a diphenylacetonitrile moiety, which consists of a diphenylmethane linked to and acetonitrile to form 2,2-diphenylacetonitrile.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylacetonitriles
Direct Parent
Diphenylacetonitriles
Alternative Parents
Diphenylmethanes / Alpha amino acid amides / Piperidinecarboxamides / Aralkylamines / Aminopiperidines / Trialkylamines / Primary carboxylic acid amides / Nitriles / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
4-aminopiperidine / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Carbonitrile / Carbonyl group
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
4RP92LYZ2F
CAS number
302-41-0
InChI Key
IHEHEFLXQFOQJO-UHFFFAOYSA-N
InChI
InChI=1S/C27H34N4O/c28-22-26(23-10-4-1-5-11-23,24-12-6-2-7-13-24)14-19-30-20-15-27(16-21-30,25(29)32)31-17-8-3-9-18-31/h1-2,4-7,10-13H,3,8-9,14-21H2,(H2,29,32)
IUPAC Name
1'-(3-cyano-3,3-diphenylpropyl)-[1,4'-bipiperidine]-4'-carboxamide
SMILES
NC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)N1CCCCC1

References

General References
Not Available
Human Metabolome Database
HMDB0041990
PubChem Compound
9331
PubChem Substance
347828727
ChemSpider
8967
RxNav
8354
ChEBI
135699
ChEMBL
CHEMBL559288
ZINC
ZINC000000538198
Wikipedia
Piritramide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedSupportive CarePost Operative Nausea and Vomiting (PONV) / Postoperative pain1
4CompletedTreatmentMalignant Neoplasm of Colon / Minimal Residual Disease1
4CompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentAortic Valve Surgery / Postoperative pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00998 mg/mLALOGPS
logP3.71ALOGPS
logP3.39ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)15.72ChemAxon
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area73.36 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity139.81 m3·mol-1ChemAxon
Polarizability49.45 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 16:35 / Updated on June 12, 2020 11:42

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates